Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, Inc. (TBPH), sold 62,134 shares at $18.75 ($1.2M) on 2025-12-03, disclosed to the SEC on 2025-12-05.
Scheduled sale ($1.2M) by SVP, COMM & MEDICAL AFFAIRS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.75 | 7,766 | $146K | 12.5% |
| 2 | $18.75 | 7,766 | $146K | 12.5% |
| 3 | $18.75 | 7,767 | $146K | 12.5% |
| 4 | $18.75 | 7,767 | $146K | 12.5% |
| 5 | $18.75 | 15,534 | $291K | 25.0% |
| 6 | $18.75 | 15,534 |
| $291K |
| 25.0% |
| Total | $18.75 avg | 62,134 | $1.2M | 100% |
| Filing → |
| TBPH | SELL | 2026-03-18 | $650K | — | Filing → |
| TBPH | SELL | 2025-07-16 | $174K | — | Filing → |
| TBPH | SELL | 2025-06-04 | $264K | — | Filing → |